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INTRODUCTION
Drug-induced liver injury (DILI) is a term that describes ab-
normalities in liver function tests (LFTs) that are attributable 
to medication intake.
1 DILI accounts for more than 50% of acu-
te liver failures and is the most common cause of the withdra-
wal of drugs from the pharmaceutical market.
2,3
Eli Lilly and Company informed healthcare professionals 
that there had been some postmarketing reports of cholestatic 
jaundice and hepatitis in patients with chronic liver disease or 
cirrhosis receiving duloxetine in late 2005. In addition, the pro-
duct labeling was modified by stating that duloxetine should 
not ordinarily be prescribed to patients with chronic alcohol use 
or evidence of chronic liver disease. 
Duloxetine was approved in Korea for major depressive dis-
order (MDD), generalized anxiety disorder, and diabetic pe-
ripheral neuropathic pain (DPNP) in 2009. It is a balanced and 
potent serotonin-norepinephrine reuptake inhibitor, and has 
been prescribed increasingly in Korea. However, data regard-
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ing its effects on the liver are not well known in this country. 
We have previously reported a case of duloxetine-induced liver 
injury in a patient with MDD.
4 
We have now experienced another three cases involving 
duloxetine-induced liver injury. Thus, we describe herein a case 
series of liver injury in patients with MDD. A MEDLINE se-
arch revealed no other report related to duloxetine-induced 
liver injury in Asian patients; this therefore appears to be the 
first reported case thereof in Asia. 
CASES
Case 1
A 22-year-old Korean male visited our clinic due to depres-
sion. The patient had no relevant medical history and no his-
tory of substance abuse; his laboratory tests were also normal. 
He was diagnosed with MDD, and initially treated with duloxe-
tine at 30 mg/day. After 3 weeks, the dosage was increased to 
60 mg/day. However, the patient had only a partial response 
and complained of fatigue. Laboratory tests were performed, 
and his total bilirubin was 1.8 mg/dL and alanine transaminase 
(ALT) was 60 U/L (See Table 1 for normal range in our hospi-
tal). Thus, duloxetine was immediately discontinued and re-
placed by escitalopram. Liver function had normalized by 4 
months after the discontinuation of duloxetine, at which time 
the patient’s total bilirubin and ALT levels were 1.2 mg/dL and 
7 U/L, respectively.
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Duloxetine-Induced Liver Injury
Case 2
A 65-year-old Korean female with a 6-month history of 
MDD was admitted to our hospital. She had attempted suicide 
by taking 5 mg of clonazepam (ten tablets) before her arrival 
at the emergency room. Fortunately, the patient’s laboratory 
findings were near normal at that time. The results of LFTs 
were as follows (See Table 1 for normal range): total protein, 
6.5 g/dL; albumin, 3.2 g/dL; total bilirubin, 1.5 mg/dL; ALT, 9 
U/L; aspartate transaminase (AST), 17 U/L; amylase, 75 U/L; 
hepatitis B virus surface antigen (HBs Ag), positive; and hep-
atitis B virus surface antibody, negative. This patient was ini-
tially treated from 2 days after admission with duloxetine at 30 
mg/day; after 4 days, the dosage increased to 60 mg/day. LFTs 
were repeated 1 week after the commencement of duloxetine 
treatment. Although the patient’s clinical status improved, the 
results of her LFTs were aggravated: total protein, 5.4 g/dL; 
albumin, 3.0 g/dL; total bilirubin, 0.9 mg/dL; ALT, 52 U/L; AST, 
43 U/L; and amylase, 101 U/L. Duloxetine was thought to be 
responsible for this deterioration of liver function, and so 
was discontinued immediately and replaced by mirtazapine. 
One week following duloxetine discontinuation, LFTs were 
once again repeated and were found to have improved: total 
protein, 6.6 g/dL; albumin, 3.6 g/dL; total bilirubin, 0.9 mg/dL; 
ALT, 31 U/L; AST, 27 U/L; and amylase, 104 U/L.
Case 3
A 37-year-old Korean male with MDD was admitted to 
our department in July 2009. This patient had been involved 
in a traffic accident in December 2008, in which he had suf-
fered an epidural hematoma and facial bone fracture. He sub-
mitted to corrective surgery in the Department of Neurosur-
gery and was medicated with valproate to prevent seizures. In 
April 2009 he was referred to our department because of de-
pression, at which time venlafaxine and quetiapine were add-
ed to the valproate. Thus, between April and July 2009 the pa-
tient had been continually medicated with venlafaxine at 75 mg/ 
day, quetiapine at 400 mg/day, and valproate at 1,200 mg/day. 
After July 2009, venlafaxine was replaced by duloxetine due to 
the persistence of depression. Laboratory findings including 
LFTs were normal before duloxetine treatment: total protein, 
7.2 g/dL; albumin, 3.9 g/dL; total bilirubin, 0.3 mg/dL; ALT, 
22 U/L; and AST, 14 U/L.
After discharge, the patient was maintained on quetiapine 
(400 mg/day), duloxetine (60 mg/day), and valproate (900 mg/ 
day) combination therapy for 5 months, after which LFTs were 
repeated. Although he did not complain of any symptoms, the 
patient’s ALT and AST levels had increased to 69 U/L and 42 
U/L, respectively, while the other LFT parameters were within 
normal limits. The patient was observed for a further 3 months 
without changing medication, and then the LFTs were repeat-
ed; ALT and AST levels further aggravated to 197 U/L and 93 
U/L, respectively. Duloxetine was therefore discontinued im-
mediately. 
DISCUSSION
Some clinical studies have found a relationship between li-
ver injury and medication with duloxetine. In patients with a 
normal baseline ALT, both ALT and AST values peaked after 
8 weeks of duloxetine medication, and alkaline phosphatase 
(ALP) steadily increased to a maximum value at 52 weeks.
5 
We previously reported the jaundice after duloxetine treatment 
in a healthy young adult without preexisting risk factors.
4 
All of our cases were medicated with duloxetine at a high do-
sage (60 mg/day). In an analysis that included postapproval 
trials, the ALT level was higher than three times the upper li-
mit of normal (ULN) in approximately 1% of duloxetine-treat-
ed patients; there is evidence that these elevations of ALT and 
AST are dose dependent.
6 Duloxetine treatment for DPNP 
was associated with a significant increase in ALP levels.
7 In par-
ticular, the high-dosage group exhibited a significant increase 
in γ-glutamyl transferase. In a published case, hepatic failure oc-
curred 6 weeks after the daily dose was increased from 30 to 
60 mg.
8
The US FDA defines DILI as a persistent elevation of at least 
three times the ULN in ALT levels accompanied by jaundice 
(total bilirubin greater than or equal to twice the ULN).
9 Based 
on this definition, two of our cases (1 and 2) are not authentic 
DILI. However, in case 1 the elevation of ALT was accompani-
ed by an elevation of total bilirubin, and in case 2 the elevation 
of ALT was accompanied by the aggravation of protein, albu-
min, and amylase. In case 2 the abnormal LFT findings were 
detected early (1 week after duloxetine treatment) and duloxe-
tine medication ceased immediately. Otherwise, severe DILI 
might have developed in this case. 
Our cases have a temporal relationship between duloxetine 
treatment and DILI. In case 1 the patient was a young and he-
althy adult without medical or substance abuse history. Th-
Table 1. Normal ranges of LFT parameters in our hospital labora-
tory
LFT Normal range
Protein 6.6-8.3 g/dL
Albumin 3.5-5.2 g/dL
Total bilirubin 0.2-1.3 mg/dL
ALT <40 U/L
AST <40 U/L
Amylase 22-85 U/L
LFT: liver function test, ALT: alanine transaminase, AST: aspartate 
transaminaseSG Kang et al. 
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erefore, the cause of DILI could be attributed to duloxetine. 
In contrast, in case 2 the patient had attempted suicide by tak-
ing clonazepam, intoxication with which might be the cause 
of DILI. However, the LFTs findings after clonazepam over-
dose were normal and her liver function was aggravated only 
after duloxetine treatment; discontinuation thereof normal-
ized her liver function. Valproate is also known to cause DILI. 
However, the liver function of case 3, who was medicated con-
tinuously for several months with valproate, venlafaxine, and 
quetiapine was normal. DILI developed only after venlafaxine 
was replaced by duloxetine. It is therefore probable that du-
loxetine alone was responsible for the DILI, or at the very least, 
a synergic effect of valproate and duloxetine caused his DILI.
Individuals with preexisting chronic liver disease or exces-
sive alcohol consumption are at a greater risk of duloxetine-in-
duced liver injury.
10 However, our cases did not have those risk 
factors. Regarding case 2, she was positive for HBs Ag. Thus, 
it is suggested that clinicians should monitor liver function 
carefully after duloxetine treatment in patients with HBs Ag.
It may be concluded that the administration of duloxetine 
can induce liver injury in patients with MDD. Although the 
mechanism underlying the observed liver injury in these cases 
remains unclear, clinicians should monitor liver function care-
fully during duloxetine treatment. Further investigations with 
larger samples are needed.
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